NIH Tissue Chip Funding Information

Tissue Chip Funding Information

The following information is reproduced from, https://ncats.nih.gov/tissuechip/funding

NIH,* the Defense Advanced Research Projects Agency (DARPA), and the Food and Drug Administration launched the Tissue Chip for Drug Screening program to develop 3-D human tissue chips containing bioengineered models that mimic human physiology. The aim is to use these chips to better predict the safety and effectiveness of candidate drugs. Scientists now are collaborating to combine the chips into an integrated system or human-body-on-a-chip.

2016 Funding Announcements

NOT-TR-16-018:(link is external)

Notice of Intent to Publish a Funding Opportunity Announcement for the NIH-CASIS Coordinated Program in Tissue Chip Systems Translational Research in Space (UH2/UH3)

PA-16-178(link is external):
Limited Competition: Tissue Chips and Missing Organs (Admin Supp)

PA-16-173(link is external):
Limited Competition: Tissue Chips for Rare Diseases (Admin Supp)

RFA-TR-16-006(link is external):
Tissue Chip Testing Centers: Validating Microphysiological Systems (U24)

• Tissue Chip Specifications (Excel - 21KB)
• Confidential Disclosure Agreement (PDF - 27KB)
• Collaborative Research Agreement (PDF - 110KB)

Budget Change FAQ:

Q:  What happens if an applicant exceeds the budget cap stated in the FOA?

A:  If an applicant proposes a budget that exceeds the DIRECT COST cap, NCATS administration will work with the applicant to adjust the budget and scope according to the number of awards made.

2014 Project Awards

In fiscal year 2014, NIH awarded(link is external) approximately $17 million to 11 institutions to support collaborative research studies over the next three years to refine existing 3-D human tissue chips and combine them into an integrated system.

2012 Project Awards

In fiscal year 2012, NIH awarded(link is external)11 two-year projects to support studies to develop 3-D cellular microsystems that represent a number of human organ systems. It also awarded eight two-year projects that will explore the potential of stem and progenitor cells to differentiate into multiple cell types that represent the cellular architecture within organ systems. NCATS contributed about $9 million for these awards; the NIH Common Fund provided about $4 million.

These studies were evaluated after two years to ensure milestones were met for a second, three-year award to integrate the models at the organ or systems level with DARPA- and NIH-funded investigators.

2011 Funding Announcements

• RFA-RM-11-022 (link is external)
  : Integrated Microphysiological Systems for Drug Efficacy and Toxicity Testing in Human Health and Disease (UH2/UH3)
• RFA-RM-12-001 (link is external)
  : Stem/Progenitor Cell-Derived Human Micro-Organs and -Tissues (U18)

*NCATS acknowledges the following NIH Institutes and Centers for their contribution to this trans-NIH program: Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute; National Eye Institute; National Heart, Lung and Blood Institute; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research; and National Institute on Drug Abuse. NIH’s Common Fund and National Institute of Neurological Disorders and Stroke initially led trans-NIH efforts to establish the program.